Analysis of clinical significance of quantitative expression of VEGF mRNA and uPA mRNA in pancreatic cancer tissue

Xi PengCheng; Shi KaiWang; Zhu Xiang; Yang KunXing; Liu ZiJun; Bian JianMin; Zhao YouCai

doi:10.3969/j.issn.1001-5256.2014.08.014

Issue 8

Aug. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(8): 752-756

PDF( 1601 KB)

Analysis of clinical significance of quantitative expression of VEGF mRNA and uPA mRNA in pancreatic cancer tissue

DOI: 10.3969/j.issn.1001-5256.2014.08.014

Department of Hepatopancreatobiliary Surgery, Nanjing Hospital Affiliated to Nanjing Medical University

Research funding:

Received Date: 2014-05-16
Published Date: 2014-08-20

Abstract

Abstract

Objective To investigate the clinical significance of quantitative expression of vascular endothelial growth factor (VEGF) mRNA and urokinase- type plasminogen activator (uPA) mRNA in pancreatic cancer tissue.Methods A retrospective study was conducted on the complete data of 30 patients with a pathological diagnosis of duct adenocarcinoma who were selected from those treated by radical resection of pancreatic head carcinoma from January 2008 to December 2011.Real- time quantitative PCR was used to measure the quantitative expression of VEGF mRNA and uPA mRNA in the pancreatic cancer tissues of the 30 cases and the normal pancreatic tissues of 6 controls, and its relationship with clinicopathological factors was analyzed.Results The quantitative expression of VEGF mRNA and uPA mRNA was correlated with the histological differentiation and perineural invasion of pancreatic cancer.The quantitative expression of VEGF mRNA was significantly higher in patients with lymphatic metastasis than in those without lymphatic metastasis group (t = 20.007, P = 0.000) .The quantitative expression of uPA mRNA was significantly lower in the tumors with a diameter of ≤2 cm than in the tumors with a diameter of > 2 cm (t = 7.539, P = 0.000) .Patients with duodenal invasion had a significantly higher quantitative expression of uPA mRNA than those without duodenal invasion (t =- 2.089, P = 0.037) .The quantitative expression of uPA mRNA in stage III tumor tissues was significantly higher than that of uPA mRNA in stage I and II tumor tissues (t =- 9.450, P = 0.000) .There was a positive correlation between VEGF mRNA expression and uPA mRNA expression (r = 0.334, P = 0.000) .Conclusion The overexpression of VEGF mRNA and uPA mRNA in pancreatic cancer tissue may create an environment that enables the invasion by pancreatic cancer cells.
- pancreatic neoplasms,
- vascular endothelial growth factor A,
- urinary plasminogen activator,
- gene expression

FullText(HTML)

References(17)

References

[1]XU KC.Investigation of treatment strategy for advanced cancer according to treatment of pancreatic cancer[J].J Clin Hepatol, 2013, 29 (7) :484-488. (in Chinese) 徐克成.从胰腺癌治疗探讨进展期癌症治疗策略[J].临床肝胆病杂志, 2013, 29 (7) :484-488.

[2] JEMAL A, SIEGEL R, XU J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60 (5) :277-300.

[3]LEUNG DW, CACHIANES G, KUANG WJ, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science, 1989, 246 (4935) :1306-1309.

[4]ZORGETTO VA, SILVEIRA GG, OLIVEIRA-COSTA JP, et al.The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinicalpathological features and survival in pancreaticadenocarcinomas[J].Diagn Pathol, 2013, 8:170.

[5]WEIDNER N.Tumoral vasculary as a prognostic factor in cancer patients:the evendence continues to grow[J].J Pathol, 1998, 184 (2) :119-122.

[6]ROGERS A, SMITH MJ, DOOLAN P, et al.Invasive markers identified by gene expression profiling in pancreatic cancer[J].Pancreatology, 2012, 12 (2) :130-140.

[7]HILDENBRAND R, NIEDERGETHMANN M, MARX A, et al.Amplification of theurokinasetype plasm inogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically highrisk group[J].Am J Pathol, 2009, 174 (6) :2246-2253.

[8]DOBRILA-DINTINJANA R, VANIS N, DINTINJANA M, et al.Etiology and oncogenesis of pancreatic carcinoma[J].Coll Antropol, 2012, 36 (3) :1063-1067.

[9]ASUTHKAR S, STEPANOVA V, LEBEDEVA T, et al.Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer[J].Mol Biol Cell, 2013, 24 (17) :2620-2632.

[10]SCHLAEPI JM, WOOD JM.Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors[J].Cancer Metastasis Res, 1999, 18 (4) :473-481.

[11]NIETHAMMER AG, LUBENAU H, MIKUS G, et al.Doubleblind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGFReceptor 2 in patients with stage IV and locally advanced pancreatic cancer[J].BMC Cancer, 2012, 12:361.

[12]HBEL S, KOBURGER I, JOHN M, et al.Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab[J].J Gene Med, 2010, 12 (3) :287-300.

[13]MARTIN LK, LI X, KLEIBER B, et al.VEGF remains an interesting target in advanced pancres cancer (APCA) :results of a multi-institutional phase II study of bevacizumab, gemicitabine, and infusional 5-fluorouracil in patients with APCA[J].Ann Oncol, 2012, 23 (11) :2812-2820.

[14]HILEY CT, CHARD LS, GANGESWARAN R, et al.Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway[J].J Virol, 2013, 87 (5) :2781-2790.

[15]KINDLER HL, NIEDZWIECKI D, HOLLIS D, et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phaseⅢtrial of the Cancer and Leukemia Group B (CALGB 80303) [J].J Clin Oncol, 2010, 28 (22) :3617-3622.

[16]VAN CUTSEM E, VERVENNE WL, BENNOUNA J, et al.PhaseⅢtrial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J].J Clin Oncol, 2009, 27 (13) :2231-2237.

[17]LU JD.Novel therapeutic strategies for advanced pancreatic cancer:targeting the epidermal growth factor and vascular endothelial growth factor pathways[J].China Oncol, 2009, 19 (8) :590-596. (in Chinese) 陆嘉德.晚期胰腺癌的分子靶向治疗[J].中国癌症杂志, 2009, 19 (8) :590-596.

Relative Articles

[1]	Yang YANG, Wenhua ZHANG, Wanxiang WANG. Expression and significance of human epidermal growth factor receptor 2， vascular endothelial growth factor-A， and programmed death-ligand 1 in gallbladder cancer[J]. Journal of Clinical Hepatology, 2025, 41(4): 703-712. doi: 10.12449/JCH250416
[2]	Guodong SHI, Zipeng LU, Kuirong JIANG. Diagnosis and treatment of dyspepsia associated with pancreatic tumors[J]. Journal of Clinical Hepatology, 2023, 39(12): 2770-2774. doi: 10.3969/j.issn.1001-5256.2023.12.004
[3]	Jing WANG, Bin TAN, Zhijie ZHAO, Haochen ZHONG, Linlin QU. Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases[J]. Journal of Clinical Hepatology, 2022, 38(2): 409-414. doi: 10.3969/j.issn.1001-5256.2022.02.028
[4]	Chen Hao, Hao JianHeng, Li ZhenCheng, Xu HuiChao, Gao Yan, Miao YuChuan, Hao HuiQin, Liu Yang. Screening for differentially expressed genes in mice with autoimmune hepatitis and effect of saikosaponin-d on the expression of several differentially expressed genes[J]. Journal of Clinical Hepatology, 2020, 36(4): 840-846. doi: 10.3969/j.issn.1001-5256.2020.04.026
[5]	Dong XiaoPeng, Wang LiJuan, Zhao ChunLin, Zhang JianPing, Pan HaiBang, Yi JianFeng, Shi YuHong. A bioinformatics analysis of acute pancreatitis based on gene expression microarray and drug screening[J]. Journal of Clinical Hepatology, 2020, 36(3): 636-640. doi: 10.3969/j.issn.1001-5256.2020.03.033
[6]	Chen Jie. Pathological and differential diagnoses of exocrine pancreatic tumors[J]. Journal of Clinical Hepatology, 2013, 29(1): 45-49.
[7]	Zheng Yan, Zhang ChunQing, Wang QiZhi, Huang HaiYan, Wang ZhiNa, Wei Yuan, Xu AnTao. Differential expression of OPN, VEGF-A, and HIF-1α and its clinical significance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(1): 58-61.
[8]	Zhang WenYing, Jin ZhenDong. Endoscopic ultrasound -guided treatment for pancreatic tumor[J]. Journal of Clinical Hepatology, 2012, 28(8): 573-575+578.
[9]	Ren LiNan, Guo XiaoZhong, Zou DeLi. EG-VEGF expression and significance in pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(8): 589-591.
[10]	Gao BaoHua, Liu Bing, Zheng JianYun, Wu FangXiong, Wang Wen, Li Lei, Niu ChunYan. The study of the expression of COX-2 and CDKN2A in chronic hepatitis B and liver cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 273-276.
[11]	Li TieHan, Tang Bo, Tang JiHong, Fu BiMang, Zhu Hong, Zhang Jie. Expression of heme oxygenase in the kidney of experimental cirrhotic rat[J]. Journal of Clinical Hepatology, 2011, 27(3): 265-267.
[12]	Cheng LiangBin, Cheng Ming, Liu Yan. The effect of Kangxian ruangan granule on the expression of nuclear factor-κB gene in fibrotic rat liver[J]. Journal of Clinical Hepatology, 2010, 26(4): 410-412.
[13]	Chen LiDong, Cheng Jun, Hong Yuan, Zhang LianFeng, Han Li, Guo Jiang. Construction of the prokaryotic expression vector of NS5ATP4A gene and its expression[J]. Journal of Clinical Hepatology, 2010, 26(4): 371-373.
[14]	Wu ShiPin, Liu ZhenZhen, Zhou Jun, Huang MingHui. Analysis of differential gene expression profiles in hepatic fibrosis tissue using cDNA microarray[J]. Journal of Clinical Hepatology, 2007, 23(4): 258-260.
[15]	Zhan LingLing, Lu: XiaoPing, Li Shan, Jiang HaiXing. Relationship between the prognosis of chronic severe hepatitis and the expression of urokinase-type plasminogen activator[J]. Journal of Clinical Hepatology, 2007, 23(3): 170-171.
[20]	Wang AiMin, Wang BaoEn, Yang YueWei, Zhang Bin, Jiang LongAn, Du ShuangCun. Interstitial collagenase gene expression in patients with chronic liver disease[J]. Journal of Clinical Hepatology, 2000, 16(2): 90-91+124.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	雷后胜. 奥曲肽联合加大补液量在肝硬化难治性腹水中的作用. 航空航天医学杂志. 2024(12): 1450-1453 .
2.	王慧玲，丁晓. 早期限制性液体复苏对肝硬化上消化道出血的复苏成功率及预后影响. 青岛医药卫生. 2022(01): 50-52 .
3.	卢春燕，吴雄健. 肝硬化腹水的药物疗法. 赣南医学院学报. 2022(04): 396-398 .
4.	杨梅，王谦. 奥曲肽联合西咪替丁治疗上消化道出血患者的效果及对止血时间、血小板计数的影响. 临床医学研究与实践. 2021(07): 66-68 .
5.	刘聪. 奥曲肽联合奥美拉唑对上消化道出血的疗效探讨. 系统医学. 2021(02): 56-58 .
6.	刁利霞，莫冬林，吴宇平. 奥曲肽结合加大补液量治疗肝硬化难治性腹水的效果及对其血清学指标的影响. 北方药学. 2020(01): 55-56 .
7.	张兵，邓丹. 肝硬化难治性腹水的临床治疗效果分析. 中国继续医学教育. 2019(05): 113-115 .
8.	马陈斌. 肝硬化腹水的临床治疗应用效果观察. 世界最新医学信息文摘. 2019(27): 72+83 .
9.	何清辉. 前列地尔辅助治疗肝硬化难治性腹水的可行性分析. 慢性病学杂志. 2019(07): 1039-1041 .
10.	李青，孙咏红. 托伐普坦治疗顽固性腹水患者临床疗效及安全性. 中国实用医药. 2018(32): 131-133 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2716) PDF downloads(525)

Analysis of clinical significance of quantitative expression of VEGF mRNA and uPA mRNA in pancreatic cancer tissue

DOI: 10.3969/j.issn.1001-5256.2014.08.014